FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity

Novo Nordisk hopes to expand Wegovy® label by becoming the first GLP-1 treatment for obesity in a pill The FDA filing is based on the results of the phase 3 OASIS 4 trial that evaluated oral semaglutide 25 mg in adults with obesity or overweight1 Novo Nordisk continues to build on…